Introduction
Transcatheter valve interventions have transformed the management of valvular heart disease (VHD), especially for elderly patients at high surgical risk, and the European Society of Cardiology (ESC) and European Association of Cardiothoracic Surgery (EACTS) issued guidelines in 2017 1 Leaders in the field must consider unmet clinical needs, device safety, and optimal research approaches to address the desired outcomes of patients with VHD. Collaboration among researchers, clinicians, industry partners (including device, imaging, and pharmaceutical companies), regulators, payers, and patient organizations is critical. Accordingly, the ESC Cardiovascular Round Table (CRT) convened a dedicated workshop in October 2017 to (i) discuss the innovations and successes of transcatheter valve intervention, (ii)
Evolving applications for transcatheter aortic valve implantation
Guidelines for the management of VHD are informed by evidence from randomized controlled trials, meta-analysis, and registry data (Supplementary material online, Tables S2-S4) . 1, 8, 9 New device iterations are associated with improved outcomes and fewer complications, 4 although some that remain more common after TAVI (e.g. major vascular complications, permanent pacemaker implantation, and paravalvular regurgitation) 8 offer opportunities for continued refinement.
Younger and lower risk populations
Use of TAVI in lower risk patients has been widely documented in registries 10, 11 and accounts for a significant proportion of current practice. While clinical outcomes of TAVI compared with surgical aortic valve replacement (SAVR) are promising (Supplementary material online, Table S2 ), ongoing randomized trials with long-term follow-up are essential in this cohort ( Table 2) . 7 While lower risk patients have been enrolled in clinical trials over time, their age has remained stable ( Figure 2) . 7, 12 Thus, it remains unknown whether TAVI can be safely expanded to patients <75 years of age, irrespective of risk. A higher risk of stroke was noted for TAVI patients in early (but not later) trials (Supplementary material online, Table S2 ). Silent cerebral infarcts are common after TAVI [13] [14] [15] and sub-clinical stroke is an important consideration in younger patients, since silent infarcts may be associated with greater risk of dementia or declining cognitive Valve durability is an important consideration for younger patients, who have a longer life expectancy post-TAVI. 7 Long-term follow-up studies are awaited and standardized definitions of structural valve degeneration and bioprosthetic valve failure 19 will be essential in their interpretation. Reflecting the application of valve-in-valve therapy using TAVI devices within degenerating surgical bioprostheses, case reports of TAVI-in-TAV are emerging and this may prove a useful concept for future development. Bicuspid aortic valves are more frequent in younger patients and stenosis is frequently associated with florid calcification and concomitant aortopathy that present procedural and engineering challenges. Outcome data using existing TAVI devices are limited and further innovations remain in development. Younger patients may also develop coronary disease over time and ensuring coronary ostial access (to permit future percutaneous intervention) is an important design consideration for future TAVI devices.
Heart failure and moderate aortic stenosis
Aortic stenosis increases afterload in patients with heart failure and reduced left ventricular (LV) ejection fraction, 20, 21 and is associated with poor prognosis. 21 The hypothesis that TAVI may be a beneficial treatment for patients with moderate AS and LV dysfunction is currently being tested in the TAVR UNLOAD (Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with Advanced heart failure, NCT02661451) trial 22 which will randomize 600 such patients to TAVI plus optimal heart failure therapy or optimal heart failure therapy alone. Further important safety considerations in this cohort include the risks of permanent pacemaker implantation and paravalvular regurgitation (either of which may impact on LV remodelling and function), and whether other co-existing valve disease [e.g. MR or tricuspid regurgitation (TR)] should also be treated.
Asymptomatic severe aortic stenosis
Haemodynamic impairment resulting from AS progresses in most patients 23 regardless of the presence or absence of symptoms, thereby increasing the risk of structural consequences (e.g. LV dysfunction, myocardial scarring and injury), morbidity, and mortality ( Figure 3) . [24] [25] [26] Very severe stenosis, significant calcification, rapidly increasing aortic-jet velocity, mid-wall fibrosis, coronary artery disease, and elevated biomarker levels (natriuretic peptides or troponin) identify the highest risk patients. 24, 25, [27] [28] [29] The role of TAVI in asymptomatic severe AS will be examined in the EARLY TAVR trial which will randomize 1109 asymptomatic patients with severe AS to TAVI or routine clinical surveillance. 30 
Aortic regurgitation
Aortic regurgitation (AR) may result from several aetiologies (including degeneration of the valve cusps, bicuspid valve morphology, abnormalities of the aortic root or ascending aorta, endocarditis, or connective tissue disorders). Outcomes are poor once symptoms develop with only 30% 5 year survival. 31 Although guideline recommendations focus on surgical intervention, 1 many patients are inoperable due to advanced age or comorbidities and safe, effective nonsurgical options remain an unmet need. The anatomical and pathophysiological features of AR present unique challenges for transcatheter intervention (Figure 4) . 32 Whereas the calcified and stenotic valve provides an anchoring platform in AS, patients with AR often have coexistent dilation of the aortic root or ascending aorta that both exceeds the dimensions of current transcatheter heart valves and necessitates specific treatment. Further, the lack of calcified tissue may leave the implant unstable, resulting in a high risk of post-procedural migration or paravalvular regurgitation. These factors may limit the application of TAVI in AR, although newer devices show promise. For example, the JenaValve TM , which uses a clipping mechanism to fixate the device to the native valve leaflets, received a CE mark for patients with AR in 2013. One year follow-up in 30 such patients demonstrated a procedural success rate of 97% (one patient required SAVR), no residual Figure 3 Event-free survival according to peak aortic jet velocity.
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moderate or severe paravalvular AR at the time of discharge, and 30 day and 1 year mortality of 10% and 20%, respectively. 33 A systematic review involving 237 patients with native pure AR who underwent TAVI demonstrated device success rates of 74-100% with a 30 day all-cause mortality of 7%. 34 Similarly, in a multicentre international registry of 146 patients undergoing TAVI for AR (78 native valve, 68 failed surgical valve), device success rates were 72% and 71% in the native and failed surgical group, respectively, and higher with newer generation devices. Further technological developments and longer follow-up are needed before TAVI can be routinely recommended for pure native AR. 35 
Subclinical leaflet thrombosis: implications for treatment
Imaging before, during and after TAVI has been an essential element in rapid maturation of the procedure. However, intensified scrutiny has indicated that subclinical leaflet thrombosis affects both transcatheter and surgical bioprosthetic aortic valves more frequently than previously recognized (Supplementary material online, Table  S5 ). 36 The large majority of patients remain asymptomatic with only minor increase in pressure gradient and the clinical relevance of subclinical leaflet thrombosis remains uncertain. Increasing awareness of this phenomenon raises important clinical and research questions. Progression from subclinical leaflet thrombosis to clinical valve thrombosis is not documented and the overall number of patients with stroke or transient ischaemic attacks is small. 37 Whereas the frequency of subclinical leaflet thrombosis appears to be higher in patients undergoing TAVI compared with SAVR, structural valve deterioration appears to be more common after SAVR, suggesting that valve durability is unrelated to leaflet thrombosis. 19 Omission of oral anticoagulation following TAVI has been associated with leaflet thrombosis, 37, 38 and anticoagulant treatment resolves thrombosis and restores normal leaflet motion (but does not reduce the risk of cerebrovascular events). 37 Furthermore, subclinical leaflet thrombosis may regress spontaneously. Importantly, patients currently eligible for TAVI are generally elderly with multiple comorbidities and at higher risk of bleeding. Thus, the balance of risks and benefits associated with anticoagulation to reduce the risk of valve thrombosis is poorly defined. Current guidelines for antithrombotic therapy should be followed until more data are available (Supplementary material online, Table S6 1 ).
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Progress in mitral and tricuspid valve intervention
Success of TAVI over the last decade has generated considerable interest in new transcatheter technologies specifically designed for repair and replacement of the native mitral and tricuspid valve. However, their anatomy and pathophysiology are significantly more complex than the aortic valve-engineering and clinical progress has been slow and the evidence base is correspondingly limited. Surgery remains the gold standard but is frequently contraindicated due to left and/or right ventricular dysfunction or associated comorbidities. Moreover, only 10% of screened patients appear to be suitable for currently available transcatheter approaches, principally due to anatomical constraints. Accordingly, there is considerable unmet clinical need and scope for further innovation and development. Future challenges for clinical trials assessing transcatheter mitral and tricuspid valve interventions include the standardized definition of clinical and imaging selection criteria for different devices, and the development of simultaneous and staged approaches using complementary techniques (e.g. transcatheter ring followed by valve implant or leaflet clipping). Heart failure, MR, and TR are closely related. Thus, collaboration between surgeons, interventionists, imaging, and heart failure specialists is needed to develop consensus on study design and optimal endpoints for future clinical trials. A multidisciplinary cooperative approach will ultimately advance the field by generating evidence that can inform guidelines and facilitate adoption of effective and safe technologies.
Transcatheter mitral valve repair and replacement
Transcatheter technologies to treat MR are evolving rapidly and include devices for leaflet repair, annular reduction, chordal implantation, and valve-replacement ( Figures 5 and 6) . 42 ) were randomly assigned to edge-to-edge Mitraclip repair plus medical treatment or medical treatment alone. Edge-to-edge repair achieved reduction of MR to Grade 2þ or less in 92% of patients at the time of hospital discharge but had no impact on the primary outcome of all-cause mortality or heart failure re-hospitalization at 1 year follow up (54.6 vs. 51 .3%, OR, 1.16 ; 95% CI 0.73-1.84; P = 0.53).
Contrasting results were reported in the US-based COAPT trial, published only four weeks later. 56 In this study, 614 patients with symptomatic systolic heart failure (left ventricular ejection fraction 20-50%) and severe functional MR (EROA >30mm 2 ) were randomly assigned to edge-to-edge MitraClip repair plus optimized medical treatment or optimized medical treatment alone. Edge-to-edge repair was effective in 98% of patients and associated with dramatic reduction in the primary endpoint (hospitalization for heart failure 35.8% vs. 67 .9% per patient-year: HR 0.53, 95% CI 0.40-0.70, P < 0.001; NNT 3.1, 95% CI 1.9-7.9) and every one of ten pre-specified, statistically powered secondary endpoints (including 2 year all-cause mortality [29.1% vs. 46 .1%: HR 0.62, 95% CI 0.46-0.82, P < 0.001; NNT 5.9, 95% CI 3.9-11.7]).
Key differences in trial design, clinical characteristics and procedural outcomes may explain the radically different outcomes of these similar studies. Whilst further analysis is ongoing, the ensuing discussions and conclusions will be pivotal in driving the future of transcatheter mitral intervention.
Use of other devices for leaflet and chordal repair or direct and indirect annuloplasty has thus far been restricted to a small number of highly specialized centres within early clinical and pre-clinical trials ( Table 4) .
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Several dedicated transcatheter mitral valve replacement devices for both degenerative and functional MR are in development or undergoing evaluation in early feasibility studies. 43 These devices are bulky and currently limited to transapical delivery although transseptal solutions are anticipated. A further constraint is the risk of outflow tract obstruction resulting from device protrusion that arises more frequently in patients with a small LV or shallow aorto-mitral angle and is associated with extremely poor prognosis. 71 Careful clinical assessment coupled with detailed pre-and periprocedural multimodality imaging (which can include computer simulated implantation) is essential and many devices are now entering feasibility or early phase clinical trials (Table 5) .
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While open-heart surgical reintervention represents the standard of care in patients with degenerating mitral bioprosthetic valves or annuloplasty rings, second (or third) time surgery is associated with significant mortality and morbidity. Transcatheter mitral valve-invalve, valve-in-ring, and valve-in-mitral annular calcium procedures using TAVI devices (even via transseptal approach) are valuable options for patients who are elderly or at high or unacceptable surgical risk ( Table 6) .
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Transcatheter tricuspid valve intervention
Tricuspid regurgitation is usually associated with left-sided valve disease or pulmonary hypertension, and poorly recognized and frequently overlooked despite being associated with right heart failure, reduced quality of life and poor outcome. Surgical repair is rarely performed as a stand-alone procedure since the impact on clinical outcomes is unclear. 89 ,90 Data are presented as n (%), mean ± standard deviation, median (range), or median (interquartile range).
Reprinted with permission from Pagnesi et al. 42, 68 Data are presented as n (%), mean ± standard deviation, median (range), or median (IQR).
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Reprinted with permission from Pagnesi et al. Transcatheter strategies for tricuspid disease are still in their early stages ( Figure 7) . 42 Anatomical challenges include the large annulus, paucity of valve/annular calcification, adjacency of the right coronary artery, and fragility of the valve tissue. Current approaches under investigation in feasibility and early phase clinical trials include edge-toedge repair, coaptation enhancement, annuloplasty, heterotopic caval valve implantation and percutaneous tricuspid valve replacement ( Table 7) . [89] [90] [91] The supporting dataset is substantially smaller than for mitral interventions (which is itself limited) and evidence generation is a high priority. Major questions that need to be addressed by future trials include whether earlier intervention for TR may be beneficial, and whether combined mitral and tricuspid procedures improve procedural success and clinical outcomes.
Future perspectives
Recent advances in transcatheter management of VHD achieved by open collaboration between cardiac surgeons and cardiologists have been remarkable. This innovation cycle will continue to evolve and address remaining uncertainties concerning transcatheter heart valves, including biocompatibility, durability, thrombosis, paravalvular leak, rhythm disorders, prevention of stroke/transient ischaemic attack, and optimal antithrombotic management. Mortality and complication rates have improved substantially but continued attention is necessary to ensure selection of patients who are likely to benefit and avoid futile procedures. Baseline characteristics [e.g. New York Heart Association (NYHA) Class IV symptoms, end-stage kidney disease, or severe respiratory disease] independently predict 1-year mortality 92, 93 and subjective factors (e.g. depression, frailty) also influence outcome. The expertise of a multidisciplinary Heart Team is critical to triage patients and weigh the balance of potential risks and benefits, and support through the transition to endof-life care should be available when transcatheter or surgical intervention is deemed futile.
Training the next generation of heart valve specialists should be a high priority for the cardiovascular community and structured training is critical for physicians already in practice since new techniques often accompany new technologies. 94 The variety of interventional devices will grow exponentially and skilled operators will be needed to ensure safe and effective intervention whilst diminishing adverse outcomes related to learning curve effects. 94, 95 These individuals will not only require expertise in the technical aspects of treatment, but also in collaborative engagement with other Heart Team members (surgeons, interventional and non-interventional cardiologists, heart failure specialists, imaging specialists, anaesthesiologists, geriatricians, nurse specialists, research nurses, and data analysts), patients, and their families. 96 The ability to interact and communicate effectively across disciplines will grow in importance as the field evolves. 94 Innovative educational models that integrate cross-specialty training and both disease-oriented and procedural competence will be instrumental in generating this new breed and development of Heart Valve Centres is essential to achieving these goals.
Conclusions
Transcatheter heart valve interventions have enabled more patients to receive treatment for AS and further expansion to other manifestations of VHD seems inevitable (Take home figure) . These procedures have prolonged life and reduced symptoms for many patients who were previously considered unsuitable for surgery. Continued collaboration between academic, industry (pharmaceutical, device, and imaging), regulatory, purchaser, and patient partners is essential to identify further unmet needs and address evidence gaps to facilitate responsible expansion of this innovative and disruptive technology.
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